Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
No pe ratio figures for Kalaris Therapeutics
Kalaris Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?